Compare Incyte Corporation (INCY) vs iShares Russell 2000 ETF (IWM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs iShares Russell 2000 ETF — how do they compare? Incyte Corporation trades at $115.71 (market cap $23.11B), while iShares Russell 2000 ETF trades at $293.63. Which is the better fit depends on your goals.
| INCY | IWM | |
|---|---|---|
Market Cap | $23.11B | — |
Sector | Health | — |
52-Week High | $118.52 | $300.45 |
52-Week Low | $67.38 | $214.95 |
Enterprise Value | $19.13B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $115.66, down 1.36% on the day, with a bullish technical signal from moving averages and strong fundamental performance including a 25.02% net income margin for 2025. Recent positive news includes regulatory approvals for Opzelura in Europe and the acquisition of Vega Therapeutics, expanding its hematology portfolio. Revenue grew to $5.14 billion in 2025, with earnings beating expectations in two of the last three quarters.
The outlook remains positive given robust profitability, pipeline advancements, and a majority analyst buy rating, though risks include competitive pressures and reliance on key drug performance. The stock's current price is slightly above the consensus target of $112.78, suggesting near-term consolidation potential amid longer-term growth catalysts.
IWM, the iShares Russell 2000 ETF, trades at $292.34, down 0.6% on the day. Technical indicators are mixed with a neutral overall signal, while moving averages show a bullish bias. The ETF has seen strong institutional inflows, with firms like AIA Group and Allspring Global Investments increasing their holdings significantly in Q1 2026 (SEC 13F filings, July 2026). Small-cap stocks have outperformed large-caps year-to-date, with the Russell 2000 up approximately 20% in 2026 (24/7 Wall Street, July 17, 2026).
The outlook for IWM hinges on continued small-cap strength, which is sensitive to interest rates and economic growth. While recent performance is robust, risks include higher volatility versus large-caps and potential Fed policy shifts. Analyst sentiment is divided, with some highlighting valuation concerns versus broader market ETFs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About iShares Russell 2000 ETF
The ETF is designed to track the performance of the securities and the stocks in the Russell 2000 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on IWM →
